"We want to try and get different predictors whether it's blood tests or psychological tests which can help us understand how a patient is likely to fare with each of these drugs," says Miras
Report the product and its site to the ACCC (Australia) or FTC (USA)
Shigematsu L, Kimura R, Terai H, Mimura Y, Ito D, Bun S et al
Retatrutide, with its glucagon component that increases energy expenditure, may theoretically influence energy levels differently, but clinical trial data on subjective energy has not yet been published in detail
Unlike existing GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) or dual agonists like tirzepatide (Mounjaro, Zepbound), Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously
Factors such as diabetes, obesity, fertility history, previous pregnancy complications, and overall health can all influence the best path forward